ECSP12012261A - Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida - Google Patents
Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituidaInfo
- Publication number
- ECSP12012261A ECSP12012261A ECSP12012261A ECSP12012261A EC SP12012261 A ECSP12012261 A EC SP12012261A EC SP12012261 A ECSP12012261 A EC SP12012261A EC SP12012261 A ECSP12012261 A EC SP12012261A
- Authority
- EC
- Ecuador
- Prior art keywords
- component
- dihydroimidazo
- combinations
- quinazoline
- solvate
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004891 lapatinib Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a: * combinaciones de: componente A: uno o más compuestos 2,3-dihidroimidazo[1,2-c]quinazolina con la fórmula general (A1) o (A2), o una sal, solvato, hidrato o estereoisómero de los mismos fisiológicamente aceptable;componente B: uno o más compuestos N-(2-arilamino) aril sulfonamida con la fórmula general (B), o Lapatinib, o Paclitaxel, o una sal, solvato, hidrato o estereoisómero de los mismos fisiológicamente aceptable; y, opcionalmente,componente C: uno o más agentes farmacéuticos adicionales;donde opcionalmente alguno de los componentes o todos ellos se encuentra en la forma de una formulación farmacéutica lista para el uso para administrar en forma simultánea, concurrente, consecutiva o por separado. de manera dependiente entre sí por la ruta oral, intravenosa, tópica, por instalaciones locales, o por la ruta intraperitoneal o nasal;* uso de dichas combinaciones para la preparación de un medicamento para tratar o para la profilaxis de un tipo de cáncer; y* un conjunto de elementos que comprende una combinación con dichas características.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10160109 | 2010-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012261A true ECSP12012261A (es) | 2012-11-30 |
Family
ID=44144895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012261 ECSP12012261A (es) | 2010-04-16 | 2012-10-15 | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130184270A1 (es) |
| EP (1) | EP2558126A2 (es) |
| JP (1) | JP5886271B2 (es) |
| KR (1) | KR20130098155A (es) |
| CN (1) | CN102958540B (es) |
| AU (1) | AU2011240003A1 (es) |
| BR (1) | BR112012026480A2 (es) |
| CA (1) | CA2796253A1 (es) |
| CL (1) | CL2012002887A1 (es) |
| CO (1) | CO6620036A2 (es) |
| CR (1) | CR20120524A (es) |
| CU (1) | CU20120150A7 (es) |
| DO (1) | DOP2012000269A (es) |
| EA (1) | EA201201414A8 (es) |
| EC (1) | ECSP12012261A (es) |
| IL (1) | IL222356A0 (es) |
| MA (1) | MA34158B1 (es) |
| MX (1) | MX2012012064A (es) |
| PE (1) | PE20130191A1 (es) |
| PH (1) | PH12012502069A1 (es) |
| SG (1) | SG184550A1 (es) |
| TN (1) | TN2012000493A1 (es) |
| WO (1) | WO2011128407A2 (es) |
| ZA (1) | ZA201208616B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2014160034A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Aldehyde dehydrogenase-1 modulators and methods of use thereof |
| BR112015025304B1 (pt) | 2013-04-08 | 2022-09-27 | Bayer Pharma Aktiengesellschaft | Combinação e composição farmacêuticas compreendendo 2-amino-n-[7-metóxi-8-(3-morfolin- 4- ilpropóxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5- il]pirimidina-5-carboxamida, gs-1101 e ibrutinib, e seu uso para tratamento de linfomas |
| WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| EA201791974A1 (ru) * | 2015-03-09 | 2018-05-31 | Байер Фарма Акциенгезельшафт | Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин |
| US20180042929A1 (en) * | 2015-03-09 | 2018-02-15 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| JP6935415B2 (ja) * | 2016-03-08 | 2021-09-15 | バイエル ファーマ アクチエンゲゼルシャフト | ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類 |
| CA3068324A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| WO2019118313A1 (en) * | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| ATE411996T1 (de) * | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| JP4323793B2 (ja) | 2002-12-16 | 2009-09-02 | キヤノン株式会社 | ズームレンズ及びそれを有する光学機器 |
| DE102004064002B4 (de) | 2004-08-04 | 2019-05-09 | Continental Automotive Gmbh | System zum Überwachen einer Sensorvorrichtung |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| AU2006272837B2 (en) * | 2005-07-21 | 2012-08-23 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of MEK |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EA201001639A1 (ru) * | 2008-04-14 | 2011-06-30 | Арди Байосайенсиз, Инк. | Композиции и способы их получения и применения |
| EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
-
2011
- 2011-04-14 AU AU2011240003A patent/AU2011240003A1/en not_active Abandoned
- 2011-04-14 CA CA2796253A patent/CA2796253A1/en not_active Abandoned
- 2011-04-14 KR KR1020127029890A patent/KR20130098155A/ko not_active Withdrawn
- 2011-04-14 MX MX2012012064A patent/MX2012012064A/es unknown
- 2011-04-14 BR BR112012026480A patent/BR112012026480A2/pt not_active IP Right Cessation
- 2011-04-14 JP JP2013504278A patent/JP5886271B2/ja not_active Expired - Fee Related
- 2011-04-14 PE PE2012002028A patent/PE20130191A1/es not_active Application Discontinuation
- 2011-04-14 EP EP11714553A patent/EP2558126A2/en not_active Withdrawn
- 2011-04-14 MA MA35308A patent/MA34158B1/fr unknown
- 2011-04-14 CN CN201180029827.XA patent/CN102958540B/zh not_active Expired - Fee Related
- 2011-04-14 SG SG2012075511A patent/SG184550A1/en unknown
- 2011-04-14 US US13/640,994 patent/US20130184270A1/en not_active Abandoned
- 2011-04-14 EA EA201201414A patent/EA201201414A8/ru unknown
- 2011-04-14 WO PCT/EP2011/055917 patent/WO2011128407A2/en active Application Filing
- 2011-04-14 PH PH1/2012/502069A patent/PH12012502069A1/en unknown
-
2012
- 2012-10-11 IL IL222356A patent/IL222356A0/en unknown
- 2012-10-12 TN TNP2012000493A patent/TN2012000493A1/en unknown
- 2012-10-15 EC ECSP12012261 patent/ECSP12012261A/es unknown
- 2012-10-16 CL CL2012002887A patent/CL2012002887A1/es unknown
- 2012-10-16 DO DO2012000269A patent/DOP2012000269A/es unknown
- 2012-10-16 CU CU2012000150A patent/CU20120150A7/es unknown
- 2012-10-16 CO CO12182241A patent/CO6620036A2/es not_active Application Discontinuation
- 2012-10-16 CR CR20120524A patent/CR20120524A/es unknown
- 2012-11-15 ZA ZA2012/08616A patent/ZA201208616B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201201414A8 (ru) | 2013-12-30 |
| SG184550A1 (en) | 2012-11-29 |
| AU2011240003A1 (en) | 2012-11-08 |
| MX2012012064A (es) | 2012-12-17 |
| PH12012502069A1 (en) | 2013-02-04 |
| KR20130098155A (ko) | 2013-09-04 |
| MA34158B1 (fr) | 2013-04-03 |
| WO2011128407A9 (en) | 2011-12-22 |
| US20130184270A1 (en) | 2013-07-18 |
| CL2012002887A1 (es) | 2013-01-18 |
| ZA201208616B (en) | 2015-08-26 |
| CN102958540B (zh) | 2015-09-02 |
| PE20130191A1 (es) | 2013-02-21 |
| IL222356A0 (en) | 2012-12-31 |
| CR20120524A (es) | 2013-01-09 |
| WO2011128407A3 (en) | 2012-02-23 |
| BR112012026480A2 (pt) | 2016-08-16 |
| HK1182937A1 (en) | 2013-12-13 |
| WO2011128407A2 (en) | 2011-10-20 |
| CU20120150A7 (es) | 2013-02-26 |
| TN2012000493A1 (en) | 2014-04-01 |
| DOP2012000269A (es) | 2012-12-15 |
| JP5886271B2 (ja) | 2016-03-16 |
| CA2796253A1 (en) | 2011-10-20 |
| EA201201414A1 (ru) | 2013-04-30 |
| CN102958540A (zh) | 2013-03-06 |
| JP2013525293A (ja) | 2013-06-20 |
| EP2558126A2 (en) | 2013-02-20 |
| CO6620036A2 (es) | 2013-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012261A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida | |
| CU20130050A7 (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida | |
| SV2017005530A (es) | Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CR20180307A (es) | Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer | |
| SV2011003802A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| GT201300121A (es) | Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| SV2011004017A (es) | Tratamiento del cancer de pancreas | |
| BR112016009214A8 (pt) | uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| BR112013025410A2 (pt) | tratamento terapêutico | |
| TN2013000141A1 (en) | Substituted n-(2-arylamino) aryl sulfonamide-containing combinations | |
| BR112014001751A2 (pt) | derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio | |
| BR112012028376B8 (pt) | Derivado inusitado da síntese de ecdisterona, seu método de preparação e uso | |
| BR112014028864A2 (pt) | dosagem e formulação |